BIO

Lisa Richards is a highly experienced Family Nurse Practitioner at the University of California, San Diego Health System. She earned her Bachelor of Science and Master of Science degrees in Nursing, graduating magna cum laude, from the University of San Diego.

With over 22 years of experience in Hepatology, Lisa has developed specialized expertise in MASLD (Metabolic Associated Steatotic Liver Disease) and its related research. She currently serves as the Assistant Director of Clinical Operations at the MASLD Research Center, where she plays a pivotal role in advancing the field.

A dedicated member of the American Association for the Study of Liver Diseases (AASLD), Lisa has been honored with the prestigious title of Associate Fellow, recognizing her excellence and leadership in Hepatology.

In addition to her clinical and research work, Lisa is an active speaker and thought leader in her field. She has presented at esteemed events such as the AASLD Annual Meeting, Global Hepatology and Advanced Practice Providers (GHAPPP), and various local and regional conferences, sharing her deep knowledge and insights into Hepatology.

Known for her leadership and expertise, Lisa Richards is widely regarded as a key figure in advancing MASLD research and Hepatology care.

MASLD-MASH Content Featuring Lisa

Related Content

Serological Workup: A Step-by-Step Guide

July 2025

In this comprehensive video, Sherona Bau, NP from UCLA, breaks down the essential hepatology workup for patients with MASLD (formerly NAFLD) and MASH, offering guidance for both primary care providers and GI/hepatology specialists. Drawing from her extensive clinical experience, she outlines a systematic approach to evaluating abnormal liver ultrasound findings—starting with critical labs to rule out chronic liver conditions like hepatitis B, hepatitis C, autoimmune hepatitis, PBC, and hereditary hemochromatosis. Sherona discusses the importance of ordering ANA, AMA, ferritin, serologies, and even specialized labs like the phosphatidylethanol (PEth) test to uncover alcohol-related liver disease that may be overlooked. She emphasizes the need to screen for cardiometabolic risk factors including type 2 diabetes and dyslipidemia and highlights non-invasive tests such as FibroScan and FIB-4 to help identify patients at risk of advanced fibrosis who may benefit from specialist referral. Most importantly, Sherona addresses the fears many patients face around liver disease progression and life expectancy, encouraging early intervention and coordinated care to improve long-term outcomes. This video is a must-watch for any clinician managing steatotic liver disease.

Watch Now arrow

MASH/MASLD in Type 2 Diabetes: Concurrent Medication Management

July 2025

In this informative episode, Whitney Steinmetz, NP from Presbyterian Medical Group in Albuquerque, NM, explores how to optimize medication strategies for patients with type 2 diabetes who are also living with MASLD and MASH. She discusses why individuals with type 2 diabetes are at significantly higher risk for developing advanced liver fibrosis—highlighting the overlapping metabolic, inflammatory, and insulin-resistant pathways that accelerate liver damage. Whitney breaks down how commonly prescribed diabetes medications—like GLP-1 receptor agonists, SGLT2 inhibitors, TZDs, and dual/triple incretins—impact liver fat, inflammation, and fibrosis progression. She offers practical guidance on selecting therapies that balance glycemic control with hepatic benefits while minimizing polypharmacy. Learn which medications may offer dual cardiometabolic and hepatic advantages, and which should be avoided or used with caution in patients with cirrhosis or advanced fibrosis. Tune in for real-world insights into how advanced practice providers can take ownership of MASH management in diabetes care.

Watch Now arrow